Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Sumitomo Dainippon Pharma Co Ltd    4506   JP3495000006

SUMITOMO DAINIPPON PHARMA CO LTD (4506)
My previous session
Most popular
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Sumitomo Dainippon Pharma : Completes Manufacturing Plant for Regenerative Medicine and Cell Therapy

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/06/2018 | 10:58am CET

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Masayo Tada) announced today the completion of the Sumitomo Dainippon Manufacturing Plant for Regenerative Medicine & Cell Therapy ('SMaRT'; hereinafter, the 'Plant') at its Central Research Laboratories (Suita City, Osaka).

Comprising two aboveground levels with a total floor area of 2,915m2, the Plant is the world's first facility dedicated to the commercial manufacture of regenerative medicine and cell therapy products derived from allogeneic iPS cells. Together with partners from the industrial and academic sectors, Sumitomo Dainippon Pharma is currently engaged in the regenerative medicine and cell therapy business using allogeneic iPS cells for the treatment of age-related macular degeneration, Parkinson's disease, retinitis pigmentosa, spinal cord injury, and other ailments. The function of the Plant is the manufacture of investigational agents and early-stage commercial production.

The three points below outline the basic concept of the Plant.

Compliance with the latest regulations for quality assurance, including GCTP (Good Gene, Cellular, and Tissue-based Products Manufacturing Practice and cGMP (current Good Manufacturing Practice

Establishment of production lines with all manufacturing processes conducted basically within a closed system

Each production zone can work independently by the individual air-conditioning system in accordance with each production schedule flexibly

Operations at the Plant are scheduled to start in March 2018. The expected total construction cost is approximately 3.6 billion yen. With the opening of the Plant, Sumitomo Dainippon Pharma aims to provide innovative regenerative medicine and cell therapy products derived from iPS cells to patients the world over by further enhancing its technology and knowhow for manufacturing such products.

Contact:

Tel: +81-6-6203-1407

(C) 2018 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
SUMITOMO CHEMICAL CO LTD -2.15% 591 End-of-day quote.-28.01%
SUMITOMO DAINIPPON PHARMA CO LTD -6.00% 3760 End-of-day quote.123.01%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SUMITOMO DAINIPPON PHARMA
12/06SUMITOMO DAINIPPON PHARMA : Announces Resolution of Consolidated Patent Infringe..
AQ
11/29MANAGEMENT TRACKS : PolarityTE and Foamix hire first chief commercial officers
AQ
11/27SUMITOMO DAINIPPON PHARMA : CMS takes aim at protected drug classes, allowing st..
AQ
11/06ASIA MARKETS: Asian Markets Mixed Ahead Of U.S. Midterm Elections
DJ
11/05SUMITOMO DAINIPPON PHARMA : Sumitomo Dainippon Pharma announces the Clinical Dat..
AQ
10/18SUMITOMO DAINIPPON PHARMA : to Invest in and Start Joint Research and Developmen..
AQ
10/18Poxel Announces Third Quarter and Nine Months 2018 Financial Update
AQ
10/10Poxel closes enrolment in TIMES 2 trial of Imeglimin in Japan
AQ
09/26SUMITOMO DAINIPPON PHARMA CO LTD : Ex-dividend day for interim dividend
FA
09/21SUMITOMO DAINIPPON PHARMA : Contributes to the 2018 Hokkaido Eastern Iburi Earth..
AQ
More news
News from SeekingAlpha
07/18ADHD CHECK-UP : Which Future Medications Have The Greatest Potential? 
2017Why Is Tension Rising In The South China Sea? 
Financials (JPY)
Sales 2019 464 B
EBIT 2019 -
Net income 2019 34 351 M
Finance 2019 129 B
Yield 2019 0,53%
P/E ratio 2019 38,42
P/E ratio 2020 39,35
EV / Sales 2019 2,95x
EV / Sales 2020 2,87x
Capitalization 1 496 B
Chart SUMITOMO DAINIPPON PHARMA CO LTD
Duration : Period :
Sumitomo Dainippon Pharma Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUMITOMO DAINIPPON PHARMA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 2 430  JPY
Spread / Average Target -35%
EPS Revisions
Managers
NameTitle
Hiroshi Nomura President & Representative Director
Masayo Tada Chairman
Yoshiharu Ikeda General Manager-Research Technology
Nobuyuki Hara Director, Executive Officer & GM-Development
Hitoshi Odagiri Director, Managing Executive Officer & GM-Sales
Sector and Competitors
1st jan.Capitalization (M$)
SUMITOMO DAINIPPON PHARMA CO LTD123.01%13 267
JOHNSON & JOHNSON4.43%390 040
PFIZER24.19%254 736
NOVARTIS5.58%223 559
ROCHE HOLDING LTD.1.70%217 483
MERCK AND COMPANY36.34%199 501